1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2016

Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 95 pages

Includes 3 FREE quarterly updates

BMI View:

The combined value of Saudi Arabia's pharmaceutical and healthcare markets is the largest in the Middle East and Africa region. The Kingdom's National Transformation Program, a key part of Vision 2030, reinstates the government's commitment to improving healthcare provision in the country. Nonetheless, the rising burden of non-communicable diseases will place greater pressure on the country's health services, while opportunities for multinational pharmaceutical companies will develop in line with this. As such, we expect the private sector to play a pivotal role in healthcare expansion in Saudi Arabia over the long term, principally through private health insurance schemes.

Headline Expenditure Projections


- Pharmaceuticals: SAR31.75bn (USD8.46bn) in 2015 to SAR35.14bn (USD9.37bn) in 2016; +10.7% in both local currency and US dollar terms. Forecast in line with Q316.

- Healthcare: SAR142.86bn (USD38.10bn) in 2015 to SAR153.50bn (USD40.91bn) in 2016; +7.4% in local currency terms and US dollar terms. Forecast in line with Q316.

Table Of Contents

Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Saudi Arabia 2014-2020) 7
SWOT 9
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Saudi Arabia 2012-2020) 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Saudi Arabia 2012-2020) 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Saudi Arabia 2012-2020) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Saudi Arabia 2012-2020) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 22
Patented Drug Market Forecast 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 24
Generic Drug Market Forecast 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 26
OTC Drug Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Saudi Arabia 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Saudi Arabia 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Saudi Arabia 2014-2020) 32
Industry Risk/Reward Index 33
Middle East and Africa Risk/Reward Index - Q4 2016 33
Saudi Arabia Risk/Reward Index 41
Rewards 41
Risks 42
Regulatory Review 44
Intellectual Property Issues 45
Pricing Regime 47
Reimbursement Regime 49
Market Overview 50
Healthcare Sector 51
Table: National Transformation Plan - Key Pharmaceutical And Healthcare Objectives For 2020 53
Table: Healthcare Resources (Saudi Arabia 2010-2015) 56
Table: Healthcare Personnel (Saudi Arabia 2010-2015) 56
Table: Healthcare Activity (Saudi Arabia 2010-2015) 57
Research and Development 57
Clinical Trials 59
Epidemiology 60
Competitive Landscape 64
Research-Based Industry 64
Table: Multinational Market Activity 66
Generic Drugmakers 68
Pharmaceutical Distribution 69
Pharmaceutical Retail Sector 70
Company Profile 71
GlaxoSmithKline 71
Sanofi 74
SPIMACO 77
TABUK Pharmaceutical Manufacturing 81
Demographic Forecast 84
Demographic Outlook 84
Table: Population Headline Indicators (Saudi Arabia 1990-2025) 85
Table: Key Population Ratios (Saudi Arabia 1990-2025) 85
Table: Urban/Rural Population and Life Expectancy (Saudi Arabia 1990-2025) 86
Table: Population By Age Group (Saudi Arabia 1990-2025) 86
Table: Population By Age Group % (Saudi Arabia 1990-2025) 87
Glossary 89
Methodology 91
Pharmaceutical Expenditure Forecast Model 91
Healthcare Expenditure Forecast Model 91
Notes On Methodology 92
Risk/Reward Index Methodology 93
Index Overview 94
Table: Pharmaceutical Risk/Reward Index Indicators 94
Indicator Weightings 95

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.